CoChat

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia

Open access
Merke, Deborah P, Mallappa, Ashwini, Arlt, Wiebke, Brac de la Perriere, Aude, Lindén Hirschberg, Angelica, Juul, Anders, Newell-Price, John, Perry, Colin G, Prete, Alessandro, Rees, D Aled, Reisch, Nicole, Stikkelbroeck, Nike, Touraine, Philippe, Maltby, Kerry, Treasure, F Peter, Porter, John, Ross, Richard J · 2021 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Abstract

Context: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes. Objective: We investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion, could improve disease control. Methods: A 6-month, randomized, phase 3 study was conducted of MR-HC vs standard glucocorticoid, followed by a single-arm MR-HC extension study. Primary outcomes were change in 24-hour SD score (SDS) of androgen precursor 17-hydroxyprogesterone (17OHP) for phase 3, and efficacy, safety and tolerability of MR-HC for the extension study. Results: The phase 3 study recruited 122 adult CAH patients. Although the study failed its primary outcome at 6 months, there was evidence of better biochemical control on MR-HC, with lower 17OHP SDS at 4 (P = .007) and 12 (P = .019) weeks, and between 07:00h to 15:00h (P = .044) at 6 months. The percentage of patients with controlled 09:00h serum 17OHP (< 1200 ng/dL) was 52% at baseline, at 6 months 91% for MR-HC and 71% for standard therapy (P = .002), and 80% for MR-HC at 18 months’ extension. The median daily hydrocortisone dose was 25 mg at baseline, at 6 months 31 mg for standard therapy, and 30 mg for MR-HC, and after 18 months 20 mg MR-HC. Three adrenal crises occurred in phase 3, none on MR-HC and 4 in the extension study. MR-HC resulted in patient-reported benefit including menses restoration in 8 patients (1 on standard therapy), and 3 patient and 4 partner pregnancies (none on standard therapy). Conclusion: MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgab051

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Patient screening, randomization treatment, and follow-up. The safety population included all randomly assigned patients who received at least one dose of trial treatment. *Patients could have more than one reason for study exclusion and withdrawn patients are included in patients excluded.
Figure 1. Patient screening, randomization treatment, and follow-up. The safety population included all randomly assigned patients who received at least one dose of trial treatment. *Patients could have more than one reason for study exclusion and withdrawn patients are included in patients excluded.CC BY-NC-ND · PubMed Central
Figure 2. Twenty-four–hour endocrine profiles for 17-hydroxyprogesterone (17OHP) and androstenedione at week 24 vs baseline (geometric mean ± 95% CIs, patients meeting the criteria for the efficacy analysis) and 09:00hrs 17OHP during the extension study. A, At week 24, the 17OHP 24-hour profile for patients receiving modified-release hydrocortisone (MR-HC) was flat, and the morning rise in 17OHP observed at baseline was no longer present. B, Similar results were observed for androstenedione. Patients in the standard glucocorticoid group had improvement in hormonal control with glucocorticoid dose adjustments according to the protocol, but the pattern of hormone secretion did not change: C, 17OHP, and D, androstenedione, profiles continued to display a morning increase. At week 24, the MR-HC vs standard groups differed during the morning hours but not throughout the 24 hours for E, 17OHP, and F, androstenedione. G, During the extension study, the geometric mean 09:00h 17OHP fell from baseline into the optimal range and remained there despite a reduction in MR-HC daily dose.
Figure 2. Twenty-four–hour endocrine profiles for 17-hydroxyprogesterone (17OHP) and androstenedione at week 24 vs baseline (geometric mean ± 95% CIs, patients meeting the criteria for the efficacy analysis) and 09:00hrs 17OHP during the extension study. A, At week 24, the 17OHP 24-hour profile for patients receiving modified-release hydrocortisone (MR-HC) was flat, and the morning rise in 17OHP observed at baseline was no longer present. B, Similar results were observed for androstenedione. Patients in the standard glucocorticoid group had improvement in hormonal control with glucocorticoid dose adjustments according to the protocol, but the pattern of hormone secretion did not change: C, 17OHP, and D, androstenedione, profiles continued to display a morning increase. At week 24, the MR-HC vs standard groups differed during the morning hours but not throughout the 24 hours for E, 17OHP, and F, androstenedione. G, During the extension study, the geometric mean 09:00h 17OHP fell from baseline into the optimal range and remained there despite a reduction in MR-HC daily dose.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 121

Metadata

Authors
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., Reisch, N., Stikkelbroeck, N., Touraine, P., Maltby, K., Treasure, F. P., Porter, J., & Ross, R. J.
Affiliations
  • National Institutes of Health (US)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
  • Hospices Civils de Lyon, Fédération d’Endocrinologie, Groupement hospitalier Est, Bron Cedex, France
  • Department of Women’s and Children’s Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
  • University of Copenhagen (DK)
  • University of Sheffield (GB)
  • Queen Elizabeth University Hospital (GB)
  • Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
  • LMU Klinikum (DE)
  • Radboud University Medical Center (NL)
  • Sorbonne Université (FR)
  • Diurnal (United Kingdom) (GB)
  • Peter Treasure Statistical Services Ltd, Kings Lynn, UK
Corresponding author
Ross, Richard J
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2021-01-29
Volume
106
Issue
5
Pages
e2063-e2077
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W3127984913
Cited by
109
References
56
Citations by year
2026: 21 · 2025: 26 · 2024: 23 · 2023: 18 · 2022: 13 · 2021: 8
FWCI
4.86
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • Yearbook of pediatric endocrinology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc-nd)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
congenital adrenal hyperplasia, modified-release hydrocortisone, glucocorticoid therapy, hyperandrogenism, 17-hydroxyprogesterone, adrenal crisis, dose reduction, pregnancy, patient-reported outcomes
MeSH terms
Adrenal Hyperplasia, Congenital, Adult, Aged, Anti-Inflammatory Agents, Female, Follow-Up Studies, Humans, Hydrocortisone, Male, Middle Aged, Prognosis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.